Key Players' Offerings in the Invasive Fungal Disease (IFD) Drugs Market and Key Developments
Company Description
| Companies | Description |
| Pfizer Inc. | Its offerings include a long-standing, major portfolio and pipeline in treating invasive fungal diseases (IFD), with an emphasis on triazoles & echinocandins |
| Merck & Co. (MSD) | This unveiled Cancidas (caspofungin acetate), Noxafil (posaconazole), and other aspects. |
| Gilead Sciences, Inc. | A firm explored a liposomal formulation of Amphotericin B, called AmBisome. |
| Astellas Pharma Inc | Its R&D activities focus on Oncology, Ophthalmology, Urology, and Immunology. |
| Basilea Pharmaceutica | This emphasizes the commercialization of the azole antifungal Cresemba (isavuconazole) & the progression of a clinical-stage pipeline featuring fosmanogepix & BAL2062. |
| Cidara Therapeutics | Its prominent offering is Rezafungin, branded as REZZAYO |
| Scynexis, Inc. | A company specializes in a new class of antifungals, called triterpenoids or fungerps. |
| F2G Ltd. | It explores discovery & the development of novel therapies for life-threatening and invasive fungal infections. |
| Viatris (Mylan/Upjohn) | It has a vital portfolio of anti-infective drugs, which mainly target IFD. |
| Novartis (Sandoz) | A firm focus on crucial anti-infectives to eliminate antimicrobial resistance (AMR) and widen access to life-saving treatment. |
Invasive Fungal Disease (IFD) Drugs Market- Value Chain Analysis
R&D
- This mainly covers the identification of compounds with newer mechanisms of action, with enhanced safety, and extensive oral bioavailability.
- Key Players: F2G Ltd, Cidara Therapeutics, Inc., Scynexis, Inc., etc.
Clinical Trials & Regulatory Approvals
- Studies are increasingly leveraging adaptive designs by employing single-arm clinical trials with external controls for rare infections, while regulatory bodies are focusing on pediatric studies & approvals to overcome resistance to existing therapies.
- Key Players: University Hospital, Strasbourg, France, Basilea Pharmaceutica, Scynexis, Inc., etc.
Patient Support & Services
- Organizations are implementing financial assistance programs, therapeutic drug monitoring (TDM), & patient education to boost adherence and manage side effects.
- Key Players: Pfizer, Gilead Sciences, HealthWell Foundation, etc.
Market Growth
The global invasive fungal disease (IFD) drugs market size was estimated at USD 3.11 billion in 2025 and is predicted to increase from USD 3.29 billion in 2026 to approximately USD 5.34 billion by 2035, expanding at a CAGR of 5.55% from 2026 to 2035.
Recent Developments in the Invasive Fungal Disease (IFD) Drugs Market
- In February 2026, MedGenome unveiled MetaSeq, a blood test for rapid and more comprehensive detection of bloodstream infections.
- In September 2025, Propedix launched Dryello (tolnaftate 1%), an advanced over-the-counter antifungal treatment for Athlete's Foot (tinea pedis).
Simplify how you monitor Invasive Fungal Disease (IFD) Drugs Market growth, investments, and companies - Access the Dashboard
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
